A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Cachexia

Treatments: Drug: PF-05230901

Study type: Interventional

Funder types: Industry

Identifiers

NCT01262690

TAM-163 FIH Study 3279K1-1000;

B2291001

Details and patient eligibility

About

This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901. Each dose will be tested in a different group of subjects starting from the lowest dose.

Enrollment: 44 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects

Exclusion criteria

• History of seizures, including childhood seizures.
• History of movement disorders or related neurological conditions.
• History of head trauma associated with loss of consciousness.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

44 participants in 1 patient group

Dose

Experimental group

Description:

6 treated, 3 placebos

Treatment:

Drug: PF-05230901

Drug: PF-05230901